Registered title, quoted from ClinicalTrials.gov
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Pulmonary Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06528847, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 74 years; sex: all
Registered eligibility fields
Pathologically confirmed stage IB (AJCC TNM staging, 8th edition) lung adenocarcinoma;
Inclusion criterion 3
Pathologically diagnosed as grade 3 invasive lung adenocarcinoma according to the 2020 grading system proposed by the International Association for the Study of Lung Cancer (IASLC) Pathology Committee (poorly differentiated: any tumor with 20% or more of high-grade patterns, including solid, micropapillary, and/or complex glandular patterns);
Inclusion criterion 5
Achieved complete resection (R0) after lobectomy, bilobectomy, or sleeve resection;
Inclusion criterion 4
Patients are screened and enrolled within 4 to 12 weeks after surgery;
Inclusion criterion 10
For female participants of childbearing potential, a negative serum pregnancy test must be obtained within 7 days prior to the first dose of the study drug;
Inclusion criterion 12
Major organ functions must be normal within 7 days prior to the first dose of the study drug.
Inclusion criterion 14
Currently participating in an interventional clinical trial, or having received other investigational drugs or used investigational devices within 4 weeks prior to the first dose of the study drug;
Exclusion criterion 3
Systemic corticosteroids or immunosuppressants must have been administered continuously for 7 days within 14 days prior to the first dose of the study drug;
Exclusion criterion 4
Presence of other malignant tumors within 5 years prior to the first dose of the study drug;
Exclusion criterion 8
Performance status score of 0 or 1 (Eastern Cooperative Oncology Group (ECOG) performance status scale);
Inclusion criterion 11
No active EGFR mutations (including but not limited to exon 19 deletions, exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutations) or ALK rearrangements;
Inclusion criterion 8
Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use highly effective contraception (with an annual failure rate of less than 1%) starting from 7 days before the first dose of the study drug and continuing until 24 weeks after the last dose;
Inclusion criterion 13
Pregnant and/or breastfeeding women;
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06528847, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Participants are able to understand the informed consent form, voluntarily agree to participate, and sign the informed consent form;
- Participants must be 18 years or older and under 75 years of age on the day they sign the informed consent form;
- Pathologically confirmed stage IB (AJCC TNM staging, 8th edition) lung adenocarcinoma;
- Achieved complete resection (R0) after lobectomy, bilobectomy, or sleeve resection;
- Pathologically diagnosed as grade 3 invasive lung adenocarcinoma according to the 2020 grading system proposed by the International Association for the Study of Lung Cancer (IASLC) Pathology Committee (poorly differentiated: any tumor with 20% or more of high-grade patterns, including solid, micropapillary, and/or complex glandular patterns);
- No prior receipt of any anti-tumor treatment, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy;
- Expected survival time more than 12 weeks;
- No active EGFR mutations (including but not limited to exon 19 deletions, exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutations) or ALK rearrangements;
- Tumor PD-L1 expression ≥1% (the PD-L1 IHC 22C3 pharmDx reagent, antibody clone number: 22C3, detection platform: DAKO Autostainer Link 48);
- Patients are screened and enrolled within 4 to 12 weeks after surgery;
- Performance status score of 0 or 1 (Eastern Cooperative Oncology Group (ECOG) performance status scale);
- For female participants of childbearing potential, a negative serum pregnancy test must be obtained within 7 days prior to the first dose of the study drug;
- Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use highly effective contraception (with an annual failure rate of less than 1%) starting from 7 days before the first dose of the study drug and continuing until 24 weeks after the last dose;
- Major organ functions must be normal within 7 days prior to the first dose of the study drug.
Exclusion Criteria:
- Postoperative pathological diagnosis of mixed histological features;
- Incomplete resection (R1/R2) or wedge resection, segmentectomy;
- Currently participating in an interventional clinical trial, or having received other investigational drugs or used investigational devices within 4 weeks prior to the first dose of the study drug;
- Systemic corticosteroids or immunosuppressants must have been administered continuously for 7 days within 14 days prior to the first dose of the study drug;
- Received live vaccines (including attenuated live vaccines) within 28 days prior to the study drug administration;
- History of or currently having interstitial lung disease/condition requiring systemic corticosteroid treatment;
- History of or currently having autoimmune disease;
- Presence of other malignant tumors within 5 years prior to the first dose of the study drug;
- Presence of uncontrolled comorbidities such as cardiac, renal, gastrointestinal, or infectious diseases;
- History of allogeneic bone marrow or organ transplantation;
- History of using any antibodies or drugs targeting T-cell co-regulatory proteins (immune checkpoints), or previous treatment with anti-tumor vaccines;
- History of hypersensitivity or intolerance to antibody-based drugs, history of any rapid allergic reactions, uncontrolled asthma, or significant drug allergies;
- Pregnant and/or breastfeeding women;
- Other conditions that may affect the safety or compliance of the study drug, including but not limited to psychiatric disorders, uncontrolled large pleural effusions, or moderate to large pleural effusions requiring repeated drainage.
Quoted from ClinicalTrials.gov, NCT06528847, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06528847, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.